The authors proposed two hypotheses: first, that methamphetamine induces neuroinflammation, and second, that it alters neuronal stem cell differentiation. These are valuable hypotheses, and the ...

Objectives To investigate dynamic changes of complement regulatory protein CD46 expression and discuss its possible mechanisms. During cerebral ischaemia-reperfusion injury. Methods The middle ...

This cellular disguise, which consists of human proteins called CD46 and CD55, prevented ‘complementary proteins’ from latching onto the parasite’s surface. As a result, the white blood cells and ...

The trial results provide key insights into the clinical impact of targeting CD46 and its potential to become the next generation target in the prostate cancer treatment paradigm.

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

FG-3246 (CD46 Targeting ADC) and FG-3180 (CD46 Targeting PET Imaging Agent) Anticipate initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in the third quarter of 2025.

Complementing Anticancer Therapy: Antibody-Drug Conjugates Targeting CD46 as Prostate Cancer Treatment. If you have the appropriate software installed, you can download article citation data to the ...

FibroGen announces the sale of its China operations to AstraZeneca for $160 million, enhancing its financial stability.

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.

This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com. Forward-Looking Statements ...

FibroGen CEO Thane Wettig stated the transaction will support the company’s financial position and allow it to focus on the development of FG-3246, a CD46-targeting antibody-drug conjugate, and ...